Merck & Co., Inc. with ticker code (MRK) have now 26 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $135.00 and $103.00 with the average target price sitting at $124.29. Now with the previous closing price of $106.49 this would imply there is now a potential upside of 16.7%. Also worth taking note is the 50 day moving average now sits at $103.36 and the 200 moving average now moves to $108.19. The total market capitalization for the company now stands at 270.30B. The current share price for the company is: $106.67 USD
The potential market cap would be $315,485,719,154 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 59.26, revenue per share of $23.38 and a 5.4% return on assets.
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services for the prevention, treatment and control of disease in all major livestock and companion animal species.
